Welcome to our dedicated page for Electromed SEC filings (Ticker: ELMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Electromed, Inc. filings document formal disclosures for a Minnesota operating company focused on airway clearance technologies. Recent Form 8-K reports furnish quarterly financial results, Regulation FD investor presentations, share repurchase authorization disclosures, and material financing information tied to a senior secured revolving credit facility.
The company's proxy and shareholder-vote filings cover director elections, auditor ratification, advisory executive compensation votes, board and governance matters, and equity-compensation disclosures. These records also describe capital-allocation actions, debt covenants, financial condition updates, and exhibit materials associated with press releases, credit agreements, and investor presentations.
Electromed, Inc. (ELMD) reported that its Chief Financial Officer, Bradley M. Nagel, received equity awards on September 1, 2026. He was granted 9,600 stock options with an exercise price of $27.10 per share, scheduled to vest in three substantially equal annual installments on September 1, 2027, September 1, 2028, and September 4, 2029. He also received 4,900 shares of restricted stock, which are scheduled to vest on the same three dates. In connection with the vesting of previously awarded restricted stock, 1,102 shares were forfeited at $27.10 per share to satisfy tax withholding obligations. No Rule 10b5-1 trading plan is reported for these transactions.
Electromed, Inc. (ELMD) reported that CEO and President James L. Cunniff had 2,671 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations related to the vesting of previously awarded restricted stock. After this tax-withholding disposition, he directly holds 145,080 shares of Electromed common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Electromed, Inc. (ELMD) reported record results for the fourth quarter and fiscal year ended June 30, 2026, and announced a planned CEO transition. Fiscal 2026 net revenues increased 15.3% to $73.8 million, led by direct homecare revenue up 16.3% to $66.6 million. Gross profit rose to $57.9 million with a gross margin of 78.5%. Operating income grew to $13.9 million, or 18.8% of net revenues, compared to 15.1% in fiscal 2025. Net income was $11.3 million, or $1.30 per diluted share, up from $7.5 million or $0.85.
For Q4 2026, net revenues increased 11.6% to $19.4 million, with net income of $3.4 million and diluted EPS of $0.39. The company highlighted its 15th consecutive quarter of year-over-year revenue and profit growth and homecare revenue per sales representative of $1,145,000, above its $1,000,000–$1,100,000 target range. As of June 30, 2026, Electromed had $20.5 million in cash, no debt, working capital of $45.1 million, and shareholders’ equity of $54.0 million.
Electromed also disclosed that President and CEO Jim Cunniff notified the company of his intention to retire on or about April 2, 2027, and is expected to resign from the Board at that time. The Board has engaged an executive search firm and begun a comprehensive search for the next CEO.
Electromed, Inc. (ELMD) develops and sells the SmartVest high frequency chest wall oscillation systems for airway clearance, primarily to U.S. homecare patients with bronchiectasis, COPD overlap, cystic fibrosis and neuromuscular conditions, using a direct-to-patient and provider model that captures both manufacturer and distributor margins.
For the year ended June 30, 2026, net revenues were $73.8 million, up 15.3% from 2025, led by 16.3% homecare growth. Gross profit was $57.9 million with a 78.5% gross margin. Operating income rose to $13.9 million, and net income increased 49.9% to $11.3 million, or $1.30 diluted EPS. R&D spending was $1.3 million, focused on product enhancements and clinical evidence.
Electromed ended 2026 with $20.5 million in cash, no borrowings on a $10 million revolving credit facility, and total shareholders’ equity of $54.0 million. The company repurchased 151,911 shares in fiscal 2026 and estimates HFCWO penetration of roughly 16% among about one million diagnosed U.S. bronchiectasis patients, highlighting a large underpenetrated market, while remaining heavily dependent on Medicare, Medicaid and private payer reimbursement.
Electromed, Inc. Chief Financial Officer Bradley M. Nagel reported a small share disposition related to taxes, not an open-market trade. On the reported date, 674 shares of common stock were forfeited at $42.30 per share to cover tax withholding when previously awarded restricted stock vested. After this tax-withholding event, Nagel directly held 18,964 shares of Electromed common stock, indicating the transaction was routine and left his overall ownership largely unchanged.
Electromed, Inc. CEO and President James L. Cunniff reported a combination of stock sales and an option exercise involving the company’s common stock. On June 8, 2026, he sold a total of 9,700 shares in three open-market transactions at weighted average prices of $37.7729, $36.7975, and $36.2490 per share. The same day, he exercised employee stock options to acquire 9,700 shares at an exercise price of $17.25 per share. Following these transactions, he directly holds 147,751 shares of Electromed common stock.
Electromed, Inc.’s Chief Financial Officer, Bradley M. Nagel, reported a combination of stock option exercises and share sales on June 4, 2026. He exercised options to acquire 9,601 shares of common stock at exercise prices of $10.71 and $10.25 per share, converting derivative awards into common shares.
On the same date, he sold a total of 11,801 common shares in open-market transactions, with weighted average sale prices of approximately $36.34 for 11,620 shares and $37.11 for 181 shares. After these exercises, he retained 2,633 options at an exercise price of $10.71 expiring on June 30, 2033 and 2,166 options at $10.25 expiring on November 10, 2033.
ELMD filed a Form 144 reporting proposed sales of Common Stock. The notice lists 06/30/2024 entry of 2,200 shares described as "Restricted Stock Vesting" and a 06/04/2026 entry of 9,601 shares described as "Stock Option Exercise" with Cash indicated. The broker shown is Fidelity Brokerage Services LLC at 900 Salem Street, Smithfield, RI, and the trading venue is listed as NYSE American.
Electromed, Inc. director Kathleen Skarvan reported a combination of option exercises and share sales. On May 15, 2026, she exercised employee stock options for 40,000 shares of common stock at an exercise price of $3.82 per share.
The filing also shows four open-market sales totaling 40,000 shares of common stock on the same date, at weighted average prices of $37.33, $36.258, $35.2422, and $34.3626 per share, each executed in multiple transactions within stated price ranges. The options exercised were fully vested and related derivative positions were exhausted.